Mineralocorticoid receptor activation as an etiological factor in kidney diseases (Q38119861)

29 August 2017

title

Mineralocorticoid receptor activation as an etiological factor in kidney diseases (English)

1 reference

29 August 2017

Kohei Ueda

0 references

Miki Nagase

1 reference

29 August 2017

publication date

6 July 2013

1 reference

Clinical and experimental nephrology

29 August 2017

published in

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

16-23

1 reference

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

The role of aldosterone blockade in murine lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Aldosterone activates NF-kappaB in the collecting duct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Cell biology and pathology of podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Aldosterone induces apoptosis in rat podocytes: role of PI3-K/Akt and p38MAPK signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Early aldosterone-induced gene product regulates the epithelial sodium channel by deubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Aldosterone activates endothelial exocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

A Nuclear Receptor Atlas: macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0827-3

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

21 January 2018

1 reference

12 December 2020

Activation of peroxisome proliferator-activated receptor-γ coactivator 1α ameliorates mitochondrial dysfunction and protects podocytes from aldosterone-induced injury

1 reference

12 December 2020

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

1 reference

12 December 2020

The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis

1 reference

12 December 2020

Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors

1 reference

12 December 2020

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

12 December 2020

Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of Types 1 and 2 Diabetes Mellitus

1 reference

12 December 2020

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

1 reference

12 December 2020

[Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012]

1 reference

12 December 2020

10.1007/S10157-013-0827-3

Identifiers

DOI

1 reference

29 August 2017

1 reference